Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
569天前
CAC 40 Up Nearly 1%
French stocks gaining some ground in positive territory on Friday, continuing their upmove for the fourth consecutive session and expectations the meeting between U.S. President Donald Trump and Russian President Vladimir Putin will help bring about an end to the ongoing war in Ukraine.
RTTNews
|
28分钟前
DAX Up Nearly 0.5%, Hits 5-week High
German stocks are up in positive territory on Friday, rising for the third consecutive session, and the benchmark DAX has hit a more than 5-week high, as some strong earnings updates and hopes about a positive outcome from U.S. President Donald Trump and Russian President Vladimir Putin's meeting help underpin sentiment.
RTTNews
|
46分钟前
European Shares Extend Gains With Focus On Putin-Trump Talks
European stocks held near five-month highs on Friday amid hopes the Trump-Putin summit in Alaska might help end the war in Ukraine.
RTTNews
|
1小时28分钟前
Asian Shares Mostly Higher With Ukraine Talks In Focus
Asian stocks ended mostly higher on Friday as investors reacted to mixed economic data from China and Japan, and awaited the outcome of the Alaska summit between U.S. and Russian Presidents.
RTTNews
|
1小时50分钟前
China Economic Data Disappoints
China's industrial production, retail sales and fixed asset investment registered weaker-than-expected growth in July, strengthening calls for further policy support to rebalance the economy towards consumption. Industrial production grew 5.7 percent in July from a year ago, following June's 6.8 percent increase, the National Bureau of Statistics reported Friday.
RTTNews
|
2小时18分钟前
Yen Rises Against Majors
The Japanese yen strengthened against other major currencies in the Asian session on Friday.
RTTNews
|
2小时31分钟前
NZ Dollar Falls On Soft China Data
The New Zealand dollar weakened against other major currencies in the Asian session on Friday, after China's industrial production and retail sales logged slower growth in July.
RTTNews
|
2小时57分钟前
